Kornimate/medical-research-clean huggingface dataset:
epidural analgesia and maternal fever during labor

Conditions: Epidural Analgesia; Analgesic Effect; Fever

Summary: women who receive epidural analgesia during labor are more likely to develop fever than those who do not. maternal fever during labor can produce various harmful effects on both mothers and infants. the investigators speculate that the effect of epidural analgesia is associated with the development of maternal fever, i.e., better analgesia is associated with higher risk of maternal fever.

epidural related maternal fever (ermf) refers to the phenomenon of increased body temperature of parturient after receiving epidural analgesia during labor. women who receive epidural labor analgesia are more likely to have fever than those who do not. in a systematic review, 20-33% of parturients receiving neuraxial analgesia developed fever during labor, compared with only 5-7% of those without neuraxial analgesia. maternal fever can interfere with women's laboring process, decrease the sensitivity of the uterus and cervix to oxytocin, and lead to dystocia and increased surgical delivery rate. the investigators note that the rate of ermf is lower in patients receiving lower density neuraxial blockade. the study is designed to test the hypothesis that the effect of epidural analgesia is associated with the development of maternal fever, i.e., better analgesia is associated with higher risk of maternal fever.

Eligibility criteria:
inclusion criteria: * age ≥18 years old; * nulliparae with single term cephalic pregnancy; * preparing to give vaginal delivery under epidural analgesia. exclusion criteria: * basal body temperature ≥37.3°c; * presence of serious pregnancy complications (such as severe preeclampsia, placenta accreta, hellp \[hemolysis, elevated liver enzymes, low platelet count\] syndrome, placenta previa, abruption of placenta, or hyperthyroidism); * history of hyperthyrodism, including hyperthyrodism in pregnancy; * taking sedatives and/or analgesics within one week before planned delivery; * american society of anesthesiologists classification \>class iii; * contraindications to epidural puncture, including central nervous system diseases (such as poliomyelitis), spinal diseases (such as intraspinal mass, lumbar disc herniation, history of spinal trauma, etc.), abnormal blood coagulation, etc.; * presence of infections, including obstetric infections, systemic infections (such as sepsis, bacteremia), or infections at the puncture site or adjacent sites; * other conditions that are considered unsuitable for study participation; * refused to participate in the study.

Keywords: epidural labor analgesia analgesic effect maternal fever during labor
polymorphisms of the thiazide's receptor gene slc12a3 and development of hyponatremia

Conditions: Thiazide Diuretics Induced Hyponatremia

Summary: the purpose of this study is to detect if there are any differences in the coding region of slc12a3 gene in individuals who have had hyponatremia associated to the use of thiazides, and those thiazides consumers without hyponatremia that have demonstrated good tolerance to the drug.

this is a case control study to compare the coding region of slc12a3 gene in individuals who have had hyponatremia associated to the use of thiazides, and those thiazides consumers without hyponatremia that have demonstrated good tolerance to the drug.

Eligibility criteria:
inclusion criteria: 1. patients older than 21 years, belonging to one of the following groups: 1. patients who have had thiazide induced hyponatremia with serum sodium lower than 125 meq/l included in the institutional registry of hyponatremia (cases) 2. patients with good tolerance to chronic treatment with thiazides tha never had associated hyponatremia (controls) 2. patients with normal serum sodium measurements before the start of the thiazides exclusion criteria: 1. refusal to participate or to the informed consent process 2. unclear cause of hyponatremia, or other hyponatremia cause concomitant to thiazide diuretics 3. patients related to other individuals already included in the study
radial extracorporeal shock wave therapy versus platelet-rich plasma injection for greater trochanteric pain syndrome

Conditions: Gluteal Tendinopathy; Greater Trochanteric Pain Syndrome

Summary: greater trochanteric pain syndrome (gtps), is characterised by pain around the greater trochanter. failure of first-line management for gtps is followed by second-line treatments range from extracorporeal shock wave therapy (eswt), corticosteroid or platelet-rich plasma (prp) injections, and surgery. in a systematic reviews, prp seems a viable effective and safe alternative option for gtps after failed physical therapy. also, positive results from previous systematic reviews involving radial eswt (reswt) as a treatment for gtps. in the literature review, there is no comparison of the effectiveness of eswt and prp injection in patients with gtps. the aim of this study was to investigate the effects of reswt and prp injection on pain, hip disability, and quality of life in patients with gtps

the pain and activities of daily living, referring to the previous week, and assessments of hip function (limping) and range of motion were evaluted by harris hip score (hhs). the pain severity during rest and activity in the previous week was evaluted by visual analog scale (vas). the pain and activity limitation was evaluted by the roles and maudsley (rm). the quality of life was evaluted by the eq-5d-3l scale.

Eligibility criteria:
inclusion criteria: * \> 18 years old * complaining of pain located anterior, lateral or posterior to the great trochanter for more than 3 months * pain while lying on the affected side * local tenderness on palpation of the area of the great trochanter * mri evidence of gluteus minimus or medius tendinopathy * refractory to conservative management exclusion criteria: * presence of signs and symptoms of another cause of regional hip pain. * full-thickness tear of the involved gluteal tendons, bursa, and intra-articular structures * evidence of concomitant injury to the involved lower extremity, including radiculopathy or radiculitis, ischial tuberosity avulsion * severe knee or hip osteoarthritis * previous hip surgery or use of eswt for gtps. * acute low back pain * implanted pacemaker * vascular, neurologic, rheumatic diseases. * any neoplastic disorders * blood coagulation disorders or use of antiplatelet or anticoagulant drugs * pregnancy.
pharmacokinetics of ceftazidime-avibactam among critically-ill patients receiving cvvhdf

Conditions: Bacterial Infections

Summary: ceftazidime-avibactam is used for treatment of invasive gram-negative bacterial infections among critically ill patients, including those on continuous venovenous hemodiafiltration . however, dosing of ceftazidime-avibactam for these patients remains undefined. the purpose of this study was to evaluate the pharmacokinetics of ceftazidime and avibactam among critically-ill patients, including those receiving cvvhd. this is a registration of dr. shields' exempt project under irb approved research study study19040363

patients who received ceftazidime-avibactam as part of their clinical care were consented. emr data was collected as well as pk sampling around their dosing to include the following samples immediately pre-dose, then at the following times thereafter: 1, 2, 4, 6, and 8 hours. blood samples were collected in lithium-heparin tubes from a central venous catheter that is not being used for the continuous venovenous hemodiafiltration. the tubes were centrifuged at 2500 rpm for 10 minutes within 1 hour from collection and the samples will be frozen at 80°c. the total concentrations of ceftazidime and avibactam were determined simultaneously from plasma by using a validated hplc-tandem ms assay. noncompartmental pharmacokinetics were calculated using the linear-up and logarithmic-down trapezoidal method, based on the assumption of first-order elimination.

Eligibility criteria:
inclusion criteria: * adult patients receiving ceftazidime-avibactam as standard care exclusion criteria: * less than 18 years-old
home sleep testing in neuromuscular disease patients

Conditions: Neuromuscular Disease

Summary: lay summary patients with severe neuromuscular develop hypoventilation, which leads to elevated carbon dioxide levels. measuring only oxygen saturation levels with pulse oximetry may be inadequate. end tidal carbon dioxide levels or arterial blood gases should be measured periodically, depending on the clinical condition of the patient. a thorough review of systems will help define any problems. patients who are hypoventilating often have elevated carbon dioxide levels at night and complain of a morning headache, restlessness or nightmares, and poor quality sleep. this may cause daytime sleepiness. insufficient respiration with hypoxia may occur later, especially if the lung is damaged by chronic aspiration. we propose to evaluate the use of the nonin lifesense monitor in home evaluation of respiration, oxygen level, heart rate, and carbon dioxide level and to develop interpretation of the results that will lead to appropriate interventions for apnea, and insufficient respiration. relevance to mda fewer than one per cent of the muscular dystrophy association have pulmonologists as co-directors.late referral of progressive restrictive lung disease leads to invasive support of respiratory failure. early initiation of non invasive ventilation techniques requires patience on the part of the caregiver and exploration of mask interfaces and ventilation techniques. in addition, the development of new therapies, currently manifested through enhanced diagnostic accuracy, will require new signal for initiation and in the assessment of success or failure. aims aim 1. to assess the utility of a small portable device (lifesense monitor nonin medical inc. plymouth minnesota) with extended recording capabilty to provide accurate diagnosis of hypoventilation. aim 2. to provide an easily interpretable report defining sleep hypoxemia, hypercapnea, and apnea. aim 3. to promote early evaluation and treatment of the respiratory problems in centers that do not have pumonologists as these are essential to prognosis, whether of survival or of quality of life, in neuromuscular diseases.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of neuromuscular disease * must have home caregivers exclusion criteria: * no home caregiver

Keywords: home sleep testing neuromuscular disease neuromuscular disease patients with fev1<50% of predicted
antecedent picky eating behaviour in young children

Conditions: Child Behavior; Child Rearing; Eating Behavior; Parent-Child Relations; Parenting; Feeding and Eating Disorders of Childhood

Summary: picky eating behaviour in young children is a very common concern for parents. the aim of the study is to investigate factors during early life which are associated with a child becoming a picky eater.

singleton children from the avon longitudinal study of parents and children will be studied prospectively (n=5758-6608). parental-completion questionnaires will be used to define 'picky eating' status at age 3 years, and child and parental feeding behaviours and practices throughout the first 2 years of the child's life. multinomial logistic regression models with 3 levels of picky eating status (not, somewhat and very picky) as the dependant variables will be used to test associations with antecedent variables, first assessing variables from pregnancy, and the first and second year of life, separately, then combining all significant variables in a final model.

Eligibility criteria:
inclusion criteria: * child enrolled in alspac, singleton, parent answered question on picky eating behaviour in questionnaire exclusion criteria: * child not enrolled in alspac, multiple, parent did not answer question on picky eating behaviour in questionnaire

Keywords: picky eater fussy eater faddy eater nutrition
placebo-controlled double-blind crossover comparative study of kw-6500

Conditions: Parkinson's Disease

Summary: this is a placebo-controlled double-blind crossover comparative study of kw-6500 in parkinson's disease patients with motor response complications on levodopa therapy. the efficacy of kw-6500 is evaluated using the change of updrs part iii score at double blind period after 12 weeks subcutaneous self-injections.


Eligibility criteria:
inclusion criteria: * patients who have given written informed consent * patients who have parkinson's disease * patients who have been on a stable regimen of levodopa plus at least one other antiparkinsonian agent and who have off state * patients who meet stage 4 or 5 while in the off state and stage 0 to 3 while in the on state on the modified hoehn and yahr scale * patients who have experienced a 30% or more improvement in unified parkinson's disease rating scale (updrs) partⅲ score when tested for responsiveness to levodopa during the baseline period * patients who have at least one off state per day * patients who can understand the expression of off state, on state, and dyskinesia * patients or their families have a desire for self-injection of kw-6500 exclusion criteria: * patients with an illness of the cardiac, hematologic, hepatic, renal, pancreatic, metabolic, respiratory, gastrointestinal, endocrinologic, or neurologic system (excluding parkinson's disease) * patients with orthostatic hypotension * patients with a history of intolerance to morphine or its derivatives, sulfur, sulfur-containing pharmaceutical products, or sulfite * patients with a history of malignant syndrome * patients with a diagnosis of cancer or evidence of continued disease * patients who do not test negative in the direct coombs' test * pregnant or lactating women, women who are planning to have children, women who test positive in the pregnancy test, or women who cannot adhere to a reliable method of contraception * patients who have received mao inhibitors except selegiline * patients with a history of mental disease (excluding psychiatric symptoms associated with parkinson's disease) * patients with a mini-mental state examination score of 23 or less * patients who are taking antipsychotics or central dopamine antagonists (excluding domperidone) * patients who are receiving methyldopa or 5-ht3 receptor antagonists * patients who are receiving reserpine or papaverine * patients who have had a neurosurgical operation for parkinson's disease * patients who have had transcranial magnetic stimulation * patients with a history of drug or alcohol abuse or dependence
the effect of inhibitory kinesio taping application on spasticity, stretch reflex and motor neuron activity

Conditions: Muscle Physiology

Summary: the first aim of this study is whether the inhibitory kinesio taping application can reduce spasticity. the second aim of this study is to investigate whether the kinesio taping application have neuromodulatory activity on motor neuron and stretch reflex. hypotheses of this study: unlike healthy cases, in patients with spastic hemiplegia 1. inhibitory kinesio taping application can reduced spasticity 2. inhibitory kinesio taping application can reduced motor neuron activity and stretch reflex

this study will include 78 spastic hemiplegic patient ( 39 controlled, 39 intervention group) spasticity , soleus hmax/mmax, soleus t reflex, soleus h reflex will be evaluated in this study. inhibitory kinesio taping method will be used in intervention group for 64-66 hours. y shaped kinesio tape will be applied on spastic gastrocsoleus muscle. sham kinesio taping method will be used in controlled group for 64-66 hours. 2 pieces kinesio tape 2,5 cm width, 5 cm length will be applied on gastrocnemius medial and lateral head, 1 piece kinesio tape 5 cm width, 5 cm length will be applied on achilles tendon. spasticity, soleus hmax/mmax, soleus t reflex and h reflex will be measured pre-application (t0), after-application ( in a few minutes) (t1), after 64-66 hours ( with band applied) (t2) and after band removed (t3). spasticity in both groups will be evaluated with modified ashworth scale.

Eligibility criteria:
inclusion criteria: * unilateral ischemic/hemorrhagic stroke * first stroke attack * gastrocsoleus muscle spasticity ( modified ashworth scale 1-3) exclusion criteria: * perform surgery from the related limb * skin problems, wounds and infections * allergy to the kinesio tape material * antispastic drug use * contracture in gastrocsoleus muscle or antagonists * peripheral nerve lesion in the lower extremity * ii.motor neuron diseases

Keywords: spasticity kinesio tape stretch reflex h-reflex t-reflex
study during pregnancy of expression of mirnas in ra or sle

Conditions: Rheumatoid Arthritis; Systemic Lupus Erythematosus

Summary: rheumatoid arthritis (ra) is a systemic disease, which mainly targets joints and results in osteoarticular destruction and serious disability. when clinical symptoms (painful and swollen joints) occur, the innate and adaptive immune responses against self antigens have already been largely amplified. this might explain that even when ra patients are treated very early and aggressively, a remission of the disease can only be obtained in approximately half of them. this proportion of remission under treatment can only be achieved using treat to target strategies involving biologics, such as anti-tnf. unfortunately, less than 20% of patients remain in remission after treatment discontinuation. thus, despite the availability of 5 different types of biologics, there are still therapeutic unmet needs. however, a spontaneous, drug-free decrease of disease activity can be observed in a physiological condition, pregnancy. although most of treatments of ra have to be discontinued during pregnancy, a marked improvement, and sometimes remission, can be observed during pregnancy, with frequent post-partum flares. the situation is the opposite with an increased risk of flares in systemic lupus erythematosus (sle), a rare systemic autoimmune disease which generally progresses in flares-up and can affect nearly any organ (the skin, joints, kidneys, the brain, the heart, ...). the course of the disease remains unpredictable for a given patient, and very few biomarkers are available to help clinicians to identify patients a risk of flares. thus, safe therapeutic options remain limited, especially in patients with serious complications. a specific concern in sle is the fact that the disease usually starts in women entering their sexual and reproductive life. even with a stable condition (i.e : lupus without recent flares and no impaired renal or cardiac function) as it is medically recommended before getting pregnant, up to 40% of sle patients flare up during pregnancy. we hypothesize disease-specific and pregnancy-induced epigenetic changes, especially those regarding the pattern and levels of micrornas, could explain the clinical improvement and the risk of flares in ra and sle, respectively. a better understanding of the underlying mechanisms could help to identify new biomarkers, notably those predicting flares in sle, and therapeutic targets, by trying to mimicking or amplifying micro-rna changes observed in ra and targeting them in sle.


Eligibility criteria:
inclusion criteria: * acr criteria for sle or 2010 acr criteria for ra * absence of any known disease (control group) * pregnancy exclusion criteria: * age \<18 * other(s) disease(s) that might affect the course of pregnancy (diabetes, uncontrolled hypertension, moderate to severe renal, cardiac or function impairment)

Keywords: pregnancy mirna rheumatoid arthritis (ra) systemic lupus erythematosus (sle)
efficacy and safety of pro-148 ophthalmic solution versus systane® in the treatment of patients with dry eye syndrome

Conditions: Dry Eye Syndrome

Summary: the purpose of this study is to evaluate the efficacy and safety of pro-148 ophthalmic solution compared with systane ® ophthalmic solution for the treatment of signs and symptoms of mild-to-moderate dry eye syndrome.

a phase 2, randomized, double masked clinical, parallel-group clinical trial to evaluate the efficacy and safety of pro-148 ophthalmic solution compared with systane ® ophthalmic solution for the treatment of signs and symptoms of mild-to-moderate dry eye syndrome.

Eligibility criteria:
inclusion criteria: * patients with diagnosis of mild-to-moderate drye eye syndrome. * male or female patients. * patients 18 years of age exclusion criteria: * patients with one blind eye. * visual acuity of 20/40 in any eye * patients with history of active stage of any other concomitant ocular disease. * patients taking any medication, topically or by any other route, which could interfere with the study's results, in the 3 days prior to trial or until a time period in which residual effects could be present. * contraindications or sensitivity to any component of the study treatments. * ocular surgery within the past 3 months. * contact lens users. * females of childbearing potential )may not participate in the study if any of the following conditions exist: * they are pregnant, * they are breastfeeding, * they have a positive urine pregnancy test at screening, * they intend to become pregnant during the study, or * they do not agree to use adequate birth control methods for the duration of the study. * participation in any studies of investigational drugs within 90 days previous to the inclusion. discontinuation criteria: * patients could be discontinued before the completion of the study because of adverse events, pregnancy, protocol violations, lack of efficacy, or administrative reasons.

Keywords: pro-148 dry eye syndrome
the effect of motivational short interview model in type 2 diabetic patient in primary care in turkey

Conditions: Lifestyle-related Condition

Summary: this study designed for primary care practionars for chronic care in primary care. a new model of motivational short interview used for intervention. the aim of this study is to develop diet and exercise regimens in type 2 diabetic patients.

this is a randomized controlled trial. the pedometer for one week has given to and filling one day food intake form asked from all participants. the weights and the heights of the participants were measured and the beck depression scale for primary care, the modify moresby scale, the eq5d, the mddq and the motivation scale filled face to face with all participants. in intervention group the steps of the motivational short interview model were; increase patient awareness about his/her type 2 diabetes and its difficulties, then discuss alternative solutions for the problems the participant has and making decisions for action, and the third and fourth interview includes new alternative solutions for new difficulties if there is and promotion of self efficacy.

Eligibility criteria:
inclusion criteria: * being type 2 diabetic unless for one year * no drug changes for last three months * hba1c levels between 7-10% * bmi \>25 kg/m2 * at least %80 compliance with medical treatment * no depression exclusion criteria: * getting \>7 point from beck depression scale for primary care * using anti depressed treatment

Keywords: short interview, diabetes, lifestyle changes, primary care